Managing toxicities in patients on ceritinib therapy
Evidence & Practice Previous     Next

Managing toxicities in patients on ceritinib therapy

Diana Borthwick Lung cancer nurse specialist, Edinburgh Cancer Centre, Edinburgh
Lavinia Magee Nurse consultant thoracic oncology, Papworth Hospital NHS Foundation Trust, Cambridge
Sarah Smith Lung cancer nurse specialist, North Bristol NHS Trust, Bristol
Rachel Thomas Lung cancer nurse specialist, Guy’s and St Thomas’ NHS Foundation Trust, London

The management of patients on therapies is an important part of the lung cancer nurse specialist role. This article focuses on the use of ceritinib in patients with ALK-positive non-small cell lung cancer who have previously been treated with crizotinib, the common toxicities that may arise and how to manage them in order to improve patient experience and adherence to treatment.

Correspondence Diana.Borthwick@nhslothian.scot.nhs.uk

Cancer Nursing Practice. 15, 10,30-33. doi: 10.7748/cnp.2016.e1364c

Received: 30 September 2016

Accepted: 07 November 2016

Published in print: 12 December 2016

Peer review

This article has been subject to external double-blind peer review and checked for plagiarism using automated software

Conflict Of Interest

This supplement has been commissioned and paid for by Novartis. Novartis has funded medical writing support through Nyxeon Healthcare Communications and payment to the journal for advertorial space. All authors contributed equally to the development, design and review of this article; Novartis has reviewed and approved the content